So, you know how sometimes a stock goes on a tear and everyone gets excited, and then it takes a little breather? That's what's happening with bioAffinity Technologies Inc. (BIAF) on Thursday. Shares are down a bit in premarket trading. But here's the thing: this comes after the stock literally doubled over the last week. It's like running a marathon and then stopping for a quick sip of water.
The reason for all that running? A promising new clinical case study for the company's flagship product, the CyPath Lung test. The test is designed to diagnose pulmonary nodules—those little spots on the lungs that can be scary and often lead to invasive biopsies—without, you know, actually being invasive.
The case study, released Tuesday, is the kind of story that gets investors and doctors excited. It involved a 71-year-old former smoker with multiple pulmonary nodules. The CyPath Lung test came back with a result of "Unlikely Malignancy." A follow-up scan later confirmed the nodules were benign. For the patient, that meant avoiding an unnecessary and potentially risky procedure. For the healthcare system, it means potentially saving a lot of money and anxiety. It's a win-win that shows the test's real-world utility.
The technical stats are pretty compelling, too. In a clinical study, the noninvasive CyPath Lung test showed 92% sensitivity (catching most of the real problems), 87% specificity (correctly ruling out non-problems most of the time), and 88% overall accuracy for detecting lung cancer in small nodules less than 20 millimeters. In the world of medical diagnostics, those are numbers that make people sit up and take notice.
But the good news isn't just in the lab. The company is also seeing serious business traction. On Friday, bioAffinity reported that revenue for its CyPath Lung test grew a remarkable 87% year-over-year in 2025. Even more impressive, the actual number of tests performed skyrocketed by 99%. That's not just selling the same thing for more money; that's a lot more doctors and patients using the product.
This growth is part of a strategic shift. The company is moving away from lower-margin lab services and betting big on CyPath Lung as its high-growth flagship. And doctors are buying in—the number of physician offices and clinics ordering the test for patients jumped 67% over 2024. The company expects this trend to speed up in 2026 as it expands its sales team into new markets.
Now, here's a nuance in the numbers that's worth understanding. The company's total fiscal 2025 revenue was $6.2 million, which is actually down from $9.4 million in 2024. That might sound confusing given the 87% growth for CyPath Lung. But it highlights the transition: they're winding down other services to focus on the star product. The forecast calls for unit sales of CyPath Lung to increase by more than 100% over 2025, with revenue for the diagnostic expected to follow suit.
As for the stock action, bioAffinity shares were down 3.09% at $2.35 in Thursday's premarket. It's a pullback, sure, but context is everything. The stock is still trading far above its 52-week low of $0.69. After the kind of run it's had, a little consolidation is pretty normal. The market is essentially pausing to digest the very positive clinical and commercial news before figuring out what the next move should be.
